Company intelligence / Profile preview
Enara Bio
Oxford/London*, United Kingdomenarabio.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
Enara Bio has not yet reported clinical results but has received significant external validation through partnerships and licensing deals. The company’s pipeline includes first-in-class TCR-based therapies targeting novel Dark Antigens®, with the most advanced programs approaching clinical entry. Boehringer Ingelheim has licensed multiple antigens for off-the-shelf therapeutic vaccines in NSCLC.
- Therapeutic areas
- Oncology
- Modalities
- TCR-based immunotherapiesbispecific T-cell engagers
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Boehringer Ingelheim (antigen licensing for NSCLC vaccines)Francis Crick Institute (academic collaboration)
Beyond the preview
Go deeper on Enara Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enara Bio.